Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

http://www.wikidata.org/entity/Q51497444

about

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes DPP4 in Diabetes Genes involved in pancreatic islet cell rejuvenation Treatment of autoimmune diabetes by inhibiting the initial event A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice Reversal of muscle atrophy by Zhimu-Huangbai herb-pair via Akt/mTOR/FoxO3 signal pathway in streptozotocin-induced diabetic mice Potentiation of insulin-mediated glucose lowering without elevated hypoglycemia risk by a small molecule insulin receptor modulator Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.Oral therapy for type 1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase-4 inhibitor, examined in non-obese diabetic mice Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?The incretin system and cardiometabolic disease A novel glycated hemoglobin A1c-lowering traditional Chinese medicinal formula, identified by translational medicine study.Effects of Dipeptidyl Peptidase-4 Inhibition with MK-0431 on Syngeneic Mouse Islet Transplantation Hepatic FoxO1 acetylation is involved in oleanolic acid-induced memory of glycemic control: novel findings from Study 2.(R)-1-[(S)-(3-Cyano-thio-morpholino)carbon-yl]-2-methyl-propyl-aminium chloride dihydrate Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.Efficacy and safety of autologous bone marrow derived hematopoietic stem cell transplantation in patients with type 2 DM: A 15 months follow-up study Oleanolic acid reduces hyperglycemia beyond treatment period with Akt/FoxO1-induced suppression of hepatic gluconeogenesis in type-2 diabetic mice.Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist The durability of sitagliptin in elderly patients with type 2 diabetes.Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor.Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity.Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass.Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.Overexpressing STAMP2 improves insulin resistance in diabetic ApoE⁻/⁻/LDLR⁻/⁻ mice via macrophage polarization shift in adipose tissues Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus Genistein ameliorates hyperglycemia in a mouse model of nongenetic type 2 diabetes.Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease - a randomized controlled trial.Novel views on new-onset diabetes after transplantation: development, prevention and treatment.Development of a nongenetic mouse model of type 2 diabetes.Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.Silence of TRIB3 suppresses atherosclerosis and stabilizes plaques in diabetic ApoE-/-/LDL receptor-/- mice.Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model.Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes

P2860

Q24628948-E1448980-1266-458D-A8DA-86AB12BAC5BB Q26797335-E51E4BE2-2F66-4155-8E7A-A02D71F8D9B6 Q26827270-06078264-253F-48CE-99B2-0D840B5878B3 Q26863647-A8AB6F01-5682-4B1A-BE59-973CAC5EF829 Q27301757-D88112FC-D1BA-4CA5-9095-F07F1E9C2852 Q28540078-9A023811-70D8-463F-9C41-82987C84C73B Q28544827-BB00E3B1-96E1-441E-B13F-39B84C1DF733 Q33428789-CB7D2A82-2300-4EBB-8EC5-CE93FD7F1E4D Q33603301-14EA81AA-C902-40DF-B88B-A346353A40B6 Q33622260-132C2DEB-A36C-4A1F-982A-1BCA8CBCABCD Q33734024-6418CFCB-09BF-4E0E-9C4F-11651020B015 Q33776092-A74554C0-590D-4901-90F2-82F1D44A35ED Q34061542-2621C492-0736-4132-A4AB-F24BA24812AE Q34069011-7C76E20E-9F05-4B59-A309-04751FAA3727 Q34183986-92227DE2-B031-4866-ACDB-4682BC7E83A6 Q34272769-5E2ECC88-012B-4848-958E-DED34DA34CD7 Q34273302-C90D2F24-0B87-4910-8F2D-09F398315958 Q34278297-9224CEEB-0404-4A38-AC67-4E3DEF6B3751 Q34319707-67590F1A-195A-412C-907B-9FD4E3D3ACC8 Q34364516-1CBB2776-0BA3-4ADE-8853-5D45073F88CE Q34490178-CCE7142E-560D-44E3-A665-4A6C2FC38E18 Q34511545-DB374607-C011-4C63-8B8B-5BD2BA4B96D3 Q34575201-A117393D-2326-43FF-B2FC-E3562F1DBDAF Q34589793-92489E0E-5BAD-48C3-B535-AFFCEF6A9C31 Q34620636-A352577A-3785-4889-B61B-DA7A8CEE2893 Q34733928-32AAB01F-142A-4552-9BBF-4125ECF0568A Q34750027-82CF5028-9097-43CA-A16A-FC762BB538F0 Q35026483-20BB0429-3E8D-47D2-988A-5034B5AEE7B3 Q35034772-14219430-8DB8-4987-92DA-E92BCC06B55F Q35043622-667BEBD3-EDB2-4C84-893C-CF81CB09DA42 Q35067232-A1AB547C-4B75-4CBC-8234-35895B011984 Q35110612-A8963549-BA22-4621-9E4F-9C546146C7FC Q35139678-67E8E6C4-7998-4474-8C30-953B7D07EFAE Q35221336-9CE1413A-95A1-49EB-B2BC-99B4E6490541 Q35580004-F926E3DF-380E-4EAB-B7E9-02E800539271 Q35607330-57CFB4C2-8094-4017-B47A-EB4B99F302F5 Q35688754-D13FCBE7-6F47-4A61-AD26-2BCB06DF50A8 Q35696570-53F7431B-3BD5-4F49-919F-CB0D09DFBFF5 Q35813371-B1AA1AD0-4305-47E8-89D9-B44D14C45427 Q35909303-533E0570-4204-490F-BCF4-5FD2D99983AF

P2860

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

http://www.wikidata.org/entity/Q51497444

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Chronic inhibition of dipeptid ...... dent model of type 2 diabetes.

@en

Chronic inhibition of dipeptid ...... dent model of type 2 diabetes.

@nl

type

label

Chronic inhibition of dipeptid ...... dent model of type 2 diabetes.

@en

Chronic inhibition of dipeptid ...... dent model of type 2 diabetes.

@nl

prefLabel

Chronic inhibition of dipeptid ...... dent model of type 2 diabetes.

@en

Chronic inhibition of dipeptid ...... dent model of type 2 diabetes.

@nl

P1433

Q51497444-9A09DD95-1BCF-4A7B-A138-C63A060784D7

P1476

Q51497444-24018018-73A8-4512-8148-7FB37C9C2BB7

P2093

Q51497444-03576209-22EA-41E0-9A2D-74A61FF9897B

Q51497444-0830988E-BA6B-4B9C-B4CA-9EF0967B1B9A

Q51497444-1B1E7724-016F-4934-96E1-3EB4772F03DB

Q51497444-24361BCD-8D4D-4AD9-BFFC-328B7BA3F425

Q51497444-608EF6C5-3F8F-484A-BAD5-7648B0EC05CA

Q51497444-61C0A73E-53C8-4977-A5EE-A1A9797B3CF9

Q51497444-744B27EC-AEC2-4441-8924-43E59405EE4E

Q51497444-83393829-10D5-4FB0-8661-426CADD13852

Q51497444-9222D6A9-0419-4C3D-876A-832D649F3CDF

Q51497444-9DFB1D68-DAC7-47F1-8BF4-4611CEFEE333

P304

Q51497444-088E0F80-D7C4-4DB4-8993-516D1E3F1D79

P31

Q51497444-0F61F9A9-8A09-4707-867A-BAF11D317DF1

P356

Q51497444-512243E2-EF9F-473C-8BA0-B39361E33686

P407

Q51497444-4915ABA6-9E11-46BF-B11C-E8845E6B5097

P433

Q51497444-72B0892B-D470-42AC-8048-423FAF6E40D9

P478

Q51497444-AD5405E7-E944-4672-9153-EB91E6D554D6

P50

Q51497444-A838562A-56DD-4878-BC06-DD8EF016B008

P577

Q51497444-05464253-55A2-4CBC-AF3A-5C46DEE83BCE

P5875

Q51497444-E14BA4E7-16ED-4A65-BA0B-AF568071A324

P698

Q51497444-B3D555E0-3A7F-4049-A43F-92099CB7594E

P921

Q51497444-4A84CB2C-61C5-487D-9510-3331935B60B6

P356

P1433

P1476

Chronic inhibition of dipeptid ...... odent model of type 2 diabetes

@en

P2093

Andrew D Howard

http://www.w3.org/2001/XMLSchema#string

Bei B Zhang

http://www.w3.org/2001/XMLSchema#string

Cai Li

http://www.w3.org/2001/XMLSchema#string

David E Moller

http://www.w3.org/2001/XMLSchema#string

Emanuel Zycband

http://www.w3.org/2001/XMLSchema#string

John Woods

http://www.w3.org/2001/XMLSchema#string

Lan Zhu

http://www.w3.org/2001/XMLSchema#string

Nancy A Thornberry

http://www.w3.org/2001/XMLSchema#string

Ranabir Sinha Roy

http://www.w3.org/2001/XMLSchema#string

Yue Feng

http://www.w3.org/2001/XMLSchema#string

P304

1695-1704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB05-1602

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7050699

http://www.w3.org/2001/XMLSchema#string

P698

16731832

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes